AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34399060 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir and Dexamethasone
Number of subjects: 137870
Study 32487236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks
Number of subjects: 240
Study 32487236 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 240
Study 32487236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine maintenance (weekly infusions for 1 month, then bi-weekly for 2 months, and finally monthly for 3 months)
Number of subjects: 240
Study 32487236 — intervention group
Group type: COMPARATOR
Intervention: Standard of care ECT maintenance
Number of subjects: 240
Study 35446236 — intervention group
Group type: EXPERIMENTAL
Intervention: Current NSSI (n=402)
Number of subjects: 490
Study 35446236 — intervention group
Group type: COMPARATOR
Intervention: Lifetime NSSI (n=88)
Number of subjects: 490
Study 32102506 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (Captopril)
Number of subjects: 100
Study 32102506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35931989 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dexmedetomidine as a perineural adjuvant
Number of subjects: 55
Study 35931989 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mL 0.5% ropivacaine without dexmedetomidine)
Number of subjects: 55
Study 35931989 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dexmedetomidine
Number of subjects: 55
Study 35931989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 32234601 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR ab(+)/MOG ab(+) group
Number of subjects: 7
Study 32234601 — intervention group
Group type: COMPARATOR
Intervention: NMDAR ab(+)/MOG ab(−) group
Number of subjects: 7
Study 32234601 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed patients
Number of subjects: 7
Study 32234601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neurological sequelae
Number of subjects: 7
Study 33176381 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game group (Xbox Kinect game for 60 min, 3 sessions/week)
Number of subjects: 61
Study 33176381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise group (aerobic exercise, 3 times/week)
Number of subjects: 61
Study 33176381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 36476079 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-reading a favorite novel
Number of subjects: 0
Study 36476079 — intervention group
Group type: COMPARATOR
Intervention: Reading a new novel of interest
Number of subjects: 0
Study 36476079 — intervention group
Group type: COMPARATOR
Intervention: Reading a set of newspaper articles
Number of subjects: 0
Study 34808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulleyaconitine A tablets combined with gabapentin
Number of subjects: 75
Study 34808751 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with gabapentin
Number of subjects: 75
Study 34808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulleyaconitine A tablets
Number of subjects: 75
Study 34808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 75
Study 34808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bulleyaconitine A + gabapentin and placebo + gabapentin)
Number of subjects: 75
Study 32276179 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (90 mg/m2 on days 1, 8, 15) plus Bevacizumab (10 mg/kg on days 1, 15) every 28 days
Number of subjects: 166
Study 32276179 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) every 21 days
Number of subjects: 166
Study 33810921 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave Lithotripsy (SWL)
Number of subjects: 613
Study 33810921 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 613
Study 33148066 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker delivered home-based Wee Wheezers asthma education program
Number of subjects: 151
Study 33148066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study 34494931 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended TIP (e‐TIP)
Number of subjects: 94
Study 34494931 — intervention group
Group type: COMPARATOR
Intervention: Standard TIP (s‐TIP)
Number of subjects: 94
Study 34494931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 94
Study 34494931 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral plate width and e‐TIP technique
Number of subjects: 94
Study 35397544 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV self-testing distributed via study staff
Number of subjects: 2000
Study 35397544 — intervention group
Group type: COMPARATOR
Intervention: Information pamphlets encouraging individuals to visit a testing facility for HCV screening (Control)
Number of subjects: 2000
Study 34085614 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified reporting of positive urine cultures
Number of subjects: 100
Study 34085614 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting of positive urine cultures
Number of subjects: 100
Study 32585332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral H2O2 + external beam RT (36 Gy in 6 fractions)
Number of subjects: 12
Study 32585332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral H2O2 + external beam RT (49.5 Gy in 18 fractions)
Number of subjects: 12
Study 35678206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 0
Study 35678206 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 0
Study 35703041 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia stent
Number of subjects: 10000
Study 35703041 — intervention group
Group type: COMPARATOR
Intervention: Zilver PTX stent
Number of subjects: 10000
Study 35905792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 40
Study 35905792 — intervention group
Group type: COMPARATOR
Intervention: Health Education and Wellness (HEW)
Number of subjects: 40
Study 34526101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paramedian approach
Number of subjects: 100
Study 34526101 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided median approach
Number of subjects: 100
Study 32711396 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer encouragement
Number of subjects: 84
Study 32711396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer encouragement)
Number of subjects: 84
Study 35093535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine (T3) supplementation
Number of subjects: 220
Study 35093535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 33739980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp
Number of subjects: 70
Study 33739980 — intervention group
Group type: COMPARATOR
Intervention: Placebo clamp
Number of subjects: 70
Study 33739980 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-back and 2-back tests during clamp procedures
Number of subjects: 70
Study 33739980 — intervention group
Group type: COMPARATOR
Intervention: fMRI during placebo clamp
Number of subjects: 70
Study 33739980 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI during hyperglycaemia
Number of subjects: 70
Study 32325038 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS (5×10^9 viral particles)
Number of subjects: 24
Study 32325038 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS (2.5×10^10 viral particles)
Number of subjects: 24
Study 32325038 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS (5×10^10 viral particles)
Number of subjects: 24
Study 32325038 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS (all doses)
Number of subjects: 24
Study 32325038 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS (high-dose)
Number of subjects: 24
Study 36315433 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 15
Study 33871596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs
Number of subjects: 546
Study 36472197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BCQR)
Number of subjects: 34
Study 36472197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35729630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (state-tailored data about rates of ACEs and economic evidence)
Number of subjects: 6509
Study 35729630 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition (state-tailored data without economic evidence)
Number of subjects: 6509
Study 35729630 — intervention group
Group type: COMPARATOR
Intervention: Control condition (national data without economic evidence)
Number of subjects: 6509
Study 35729630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 6509
Study 33270026 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat intervention providing breastfeeding knowledge and promotion information weekly from third month of pregnancy to 6 months postpartum
Number of subjects: 344
Study 33270026 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat intervention
Number of subjects: 344
Study 33270026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WeChat intervention)
Number of subjects: 344
Study 34543474 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive management with Cal/BD foam (twice weekly)
Number of subjects: 521
Study 34543474 — intervention group
Group type: COMPARATOR
Intervention: Reactive management with vehicle foam (twice weekly)
Number of subjects: 521
Study 34543474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD foam (once daily) during initial 4-week phase
Number of subjects: 521
Study 34023810 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated to maximum 26 mg/day)
Number of subjects: 58
Study 32345650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
Number of subjects: 0
Study 32345650 — intervention group
Group type: COMPARATOR
Intervention: BRAVO risk engine predictions
Number of subjects: 0
Study 32216143 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 20
Study 32216143 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 20
Study 35590054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 ml
Number of subjects: 17
Study 34021976 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for automatic recognition of cephalometric landmarks
Number of subjects: 1785
Study 34021976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip and/or palate
Number of subjects: 1785
Study 34021976 — intervention group
Group type: COMPARATOR
Intervention: Dental age, orthodontic appliances, and overjet
Number of subjects: 1785
Study 36004368 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (YBLI) for 12 weeks
Number of subjects: 72
Study 36004368 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) for 12 weeks
Number of subjects: 72
Study 35075109 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone (ixa-dex)
Number of subjects: 122
Study 35075109 — intervention group
Group type: COMPARATOR
Intervention: pomalidomide-dexamethasone (pom-dex)
Number of subjects: 122
Study 35075109 — intervention group
Group type: EXPERIMENTAL
Intervention: ixa-dex
Number of subjects: 122
Study 35075109 — intervention group
Group type: COMPARATOR
Intervention: pom-dex
Number of subjects: 122
Study 35075109 — intervention group
Group type: EXPERIMENTAL
Intervention: ixa-dex vs pom-dex
Number of subjects: 122
Study 33449919 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 15
Study 33449919 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin(9-39)NH2 infusion during acarbose treatment
Number of subjects: 15
Study 33449919 — intervention group
Group type: COMPARATOR
Intervention: Exendin(9-39)NH2 infusion during placebo treatment
Number of subjects: 15
Study 32320843 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice combined with 1-week sample of nicotine replacement therapy (NRT) and active referral to smoking cessation services
Number of subjects: 1148
Study 32320843 — intervention group
Group type: COMPARATOR
Intervention: Brief advice only (usual care)
Number of subjects: 1148
Study 35894681 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity blood flow restricted walking (BFR)
Number of subjects: 16
Study 35894681 — intervention group
Group type: COMPARATOR
Intervention: Jogging
Number of subjects: 16
Study 35894681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity BFR-walking
Number of subjects: 16
Study 33874750 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i (pooled from 4 CVOTs, lowest eGFR subgroup)
Number of subjects: 4401
Study 35805342 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-biased desk
Number of subjects: 99
Study 35805342 — intervention group
Group type: COMPARATOR
Intervention: Traditional desk
Number of subjects: 99
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for vasa previa in perinatal centers
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for vasa previa in primary facilities
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of vasa previa in perinatal centers
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of vasa previa in primary facilities
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to tertiary hospital for VP diagnosis in primary facilities
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine hospitalization in perinatal centers
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid administration in perinatal centers
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Median gestational age at planned cesarean section in perinatal centers
Number of subjects: 377
Study 32281219 — intervention group
Group type: COMPARATOR
Intervention: Median gestational age at planned cesarean section in primary facilities
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival outcomes of reported cases of vasa previa
Number of subjects: 377
Study 32281219 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean section outcome
Number of subjects: 377
Study 35329011 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based core stability exercises
Number of subjects: 46
Study 35329011 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 46
Study 34819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg)
Number of subjects: 246
Study 34819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (225 mg)
Number of subjects: 246
Study 34819017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 32249589 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to migraine
Number of subjects: 59674
Study 35856361 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (15 g/bag, orally, twice a day)
Number of subjects: 143
Study 35856361 — intervention group
Group type: COMPARATOR
Intervention: CoQ10 (10 mg tablet orally, thrice daily) with Vitamin E (100 mg tablet orally, thrice daily)
Number of subjects: 143
Study 33398905 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality headset (videos)
Number of subjects: 60
Study 33398905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 36173970 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage by a rheumatologist in primary care
Number of subjects: 544
Study 36173970 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 544
Study 34275745 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program (2 face-to-face individual instructional sessions)
Number of subjects: 40
Study 34275745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 33012200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 60
Study 33012200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33930024 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent deworming
Number of subjects: 6089
Study 33930024 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status
Number of subjects: 6089
Study 33930024 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level of household head
Number of subjects: 6089
Study 33930024 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of improved sanitation facilities
Number of subjects: 6089
Study 33032778 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 800
Study 33032778 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Number of subjects: 800
Study 33032778 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-planning leaflet
Number of subjects: 800
Study 33032778 — intervention group
Group type: COMPARATOR
Intervention: Placebo for atorvastatin
Number of subjects: 800
Study 33032778 — intervention group
Group type: COMPARATOR
Intervention: Placebo for omega-3
Number of subjects: 800
Study 33032778 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 800
Study 35018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 134
Study 35018413 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 134
Study 32961034 — intervention group
Group type: EXPERIMENTAL
Intervention: Macimorelin 2.0 mg/kg
Number of subjects: 60
Study 32961034 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60
Study 32961034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32358608 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Acceptance and Commitment Therapy
Number of subjects: 30
Study 36216414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HIV/syphilis self-testing arm
Number of subjects: 330
Study 36216414 — intervention group
Group type: COMPARATOR
Intervention: Single HIVST arm
Number of subjects: 330
Study 36216414 — intervention group
Group type: COMPARATOR
Intervention: Site-based testing arm
Number of subjects: 330
Study 36216414 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 330
Study 32981856 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial angiography (TRA)
Number of subjects: 12118
Study 32981856 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral angiography (TFA)
Number of subjects: 12118
Study 34359042 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of 1.0 g/kg of 20% mannitol (immediately after anesthesia induction)
Number of subjects: 100
Study 34359042 — intervention group
Group type: COMPARATOR
Intervention: Routine administration of 1.0 g/kg of 20% mannitol (at the time of skin incision)
Number of subjects: 100
Study 34359042 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of 1.0 g/kg of 20% mannitol
Number of subjects: 100
Study 34359042 — intervention group
Group type: COMPARATOR
Intervention: Routine administration of 1.0 g/kg of 20% mannitol
Number of subjects: 100
Study 34548383 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks for 24 weeks
Number of subjects: 134
Study 34548383 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks until week 96
Number of subjects: 134
Study 34548383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 35295200 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Cryopreservation (CP)
Number of subjects: 0
Study 35295200 — intervention group
Group type: COMPARATOR
Intervention: Non-Treated (NT)
Number of subjects: 0
Study 34298559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255
Study 32622071 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU daily cholecalciferol
Number of subjects: 100
Study 32622071 — intervention group
Group type: EXPERIMENTAL
Intervention: 3750 IU daily cholecalciferol
Number of subjects: 100
Study 32622071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 35137728 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 36
Study 35137728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33647273 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acute intermittent hypoxia combined with walking practice (AIH + WALK)
Number of subjects: 11
Study 33647273 — intervention group
Group type: COMPARATOR
Intervention: SHAM combined with walking practice (SHAM + WALK)
Number of subjects: 11
Study 36201607 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine oral rinse
Number of subjects: 103
Study 36201607 — intervention group
Group type: COMPARATOR
Intervention: Listerine
Number of subjects: 103
Study 36201607 — intervention group
Group type: COMPARATOR
Intervention: Saline oral rinse
Number of subjects: 103
Study 32330117 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused compression (VasoStat; Forge Medical)
Number of subjects: 52
Study 32330117 — intervention group
Group type: COMPARATOR
Intervention: Balloon compression device (TR Band; Terumo Medical)
Number of subjects: 52
Study 32330117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 52